Nanopath announces the close of a $25 million Series B financing to advance molecular testing for women's health, co-led by Norwest and SV Health Investors.
Amount Raised
$25 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareInvestors
Description
Nanopath, a point-of-care diagnostics company, has closed a $25 million Series B financing round to support the launch of its FDA 510(k) study for a new vaginitis test. The round was co-led by Norwest and SV Health Investors' MedTech Convergence Fund, with participation from other investors. This funding will also aid in the potential expansion of Nanopath's pipeline and the growth of its team in preparation for commercialization.
Who to call at Nanopath, and when
A new round usually means Nanopath is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nanopath raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nanopath, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nanopath. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nanopath raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNanopath raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.